Tasly Pharmaceutical Group Co. Ltd. Class A 600535

SSE · China · Health Technology

CNY 14.00+0.26 (+1.89%)

Market closed· Sep 30, 2026, 7:00 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Tasly Pharmaceutical Group Co. Ltd. Class A 600535

SSE · China · Health Technology

CNY 14.00+0.26 (+1.89%)

Market closed· Sep 30, 2026, 7:00 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-2.51% · 6MFull-screen chart

Open CNY 13.75High CNY 14.10Low CNY 13.72Close CNY 14.00Volume 12.58M

Sep 30, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: CNY 13.74
Day range: CNY 13.72 – CNY 14.10
52-week range: CNY 12.90 – CNY 16.24
Volume: 12.58M
Market cap: CNY 20.76B
P/E (TTM): 17.1
Dividend yield (annualized): 2.21%
Next earnings date: 2026-10-24
Avg. volume (1Y): 11.78M

Performance

1 week

+0.79%

1 month

-4.63%

3 months

+1.74%

6 months

-1.52%

Year to date

-7.59%

1 year

-9.57%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: China
Exchange: SSE
Shares outstanding: 1.49B
Employees: 10,563
ISIN: CNE000001C81
Beta: 0.68

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMar 30, 2026

AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)

TAIPEI, Taiwan, March 30, 2026 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific antibodies, today announced the finalization of an amendment to its development collaboration with Tasly Pharmaceutical Group Co.LTD., establishing a supplementary framework for the anticipated out-licensing of AP505 (B1962) outside the original agreement’s designated Territory (which includes PRC, Hong

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.